Trial Profile
The Effect of RNS60 on ALS Biomarkers
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 24 Apr 2023
Price :
$35
*
At a glance
- Drugs RNS 60 (Primary) ; RNS 60 (Primary)
- Indications Amyotrophic lateral sclerosis
- Focus Biomarker; Pharmacodynamics
- Acronyms RNS60
- 07 Dec 2021 According to a Revalesio media release, data presented at the ALS/MND International Symposium 2021.
- 07 Dec 2021 Results presented in a Revalesio Media Release.
- 05 Nov 2021 Status changed from recruiting to completed.